Henry Schein, Inc.
Analysis
Henry Schein has moved from cleaning up after its 2023 cyberattack to growing again: sales accelerated in every quarter since and management has raised its 2026 outlook. The profit story now rests on cost savings that only land in the second half.How much of Henry Schein's $125 million savings run rate is booked?
- Growth is coming from taking share, not from a better market.
Management called end markets flat and the gains theirs: U.S. dental merchandise outgrew the market and corporate brands grew about twice as fast as other merchandise. So the growth now depends on winning customers from rivals.
- Margins turned the corner, and the fix was pricing and own brands.
Gross margin hit its low in late 2025, then rose for three straight quarters and expanded in every segment by Q2 FY2026. Management credits more disciplined pricing and faster corporate-brand sales — profit from what it already sells.How much of Henry Schein's margin gain is price versus own brands?
- The savings arrive later than the costs that create them.
Management reaffirmed over $200 million of operating profit improvement, with a $125 million run rate by the end of 2026, but says the benefit is 'more heavily weighted to the second half.' The outsourcing only started this year.Which value creation projects does Henry Schein expect to slip to 2027?
- Dental share gainsThe bull case is that Henry Schein is taking dental share back from rivals after the cyber attack, so its sales growth now outpaces a market that is barely expanding.
- Value creation savings targetManagement has put a firm deadline and a specific dollar target on its cost and pricing program, and the new chief executive has kept that commitment.
- Cloud software and AISoftware subscriptions are growing fast and are almost entirely recurring, and new artificial intelligence tools raise revenue per customer and pull through merchandise sales.
- Recurring restructuring chargesThe bear case is that earnings growth leans on repeated restructuring, and the company still cannot give a GAAP earnings forecast because it cannot size the charges.
- Respiratory test seasonalityIts medical arm sells respiratory tests whose demand swings with the flu season, so a light season removes sales that the company cannot control.
- Value implant margin dilutionFaster growth in cheaper value implants and in large dental groups dilutes gross margin, so management now stresses gross profit dollars over margin percentage.
| Politician | Transaction | Amount | Traded | Filed |
|---|---|---|---|---|
Donald Trump Republican · Executive | Purchase | ≥$15K | Aug 26 | Oct 8 |
Donald Trump Republican · Executive | Sale | ≥$15K | May 11 | Jul 1 |
Ro Khanna Democratic · House · CA-17 | Sale | ≥$1K | May 15 | Jun 9 |
Ro Khanna Democratic · House · CA-17 | Purchase | ≥$1K | Mar 30 | Apr 7 |
Michael T. McCaul Republican · House · TX-10 | Sale | ≥$15K | Jan 9 | Feb 11 |
Congressional trading data provided by QuiverQuant
How Henry Schein turned $13.2B of revenue into $600.6M of operating income.
| Revenue | ||
|---|---|---|
| Healthcare Distribution | $12.7B | |
| Technology | $509.2M | |
| Total revenue | $13.2B | |
| Operating income | $600.6M | 4.5% |